| scholarly article | Q13442814 |
| P2093 | author name string | M. L. Leong | |
| T. W. Dubensky | |||
| D. B. Kanne | |||
| P2860 | cites work | Evaluation of the Sublingual Route for Administration of Influenza H5N1 Virosomes in Combination with the Bacterial Second Messenger c-di-GMP | Q21090975 |
| Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway | Q24306635 | ||
| STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling | Q24336398 | ||
| c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response | Q24616827 | ||
| Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system | Q24633195 | ||
| STING is a direct innate immune sensor of cyclic di-GMP | Q24633648 | ||
| A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP | Q24642631 | ||
| Cyclic di-GMP: the first 25 years of a universal bacterial second messenger | Q26850396 | ||
| Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase | Q27678007 | ||
| Structure of Human cGAS Reveals a Conserved Family of Second-Messenger Enzymes in Innate Immunity | Q27678294 | ||
| Structural mechanism of cytosolic DNA sensing by cGAS | Q27678393 | ||
| Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING | Q27678540 | ||
| Structural Analysis of the STING Adaptor Protein Reveals a Hydrophobic Dimer Interface and Mode of Cyclic di-GMP Binding | Q27679046 | ||
| The structural basis for the sensing and binding of cyclic di-GMP by STING | Q27681353 | ||
| Crystal structures of STING protein reveal basis for recognition of cyclic di-GMP | Q27681354 | ||
| Novel c-di-GMP recognition modes of the mouse innate immune adaptor protein STING | Q27684230 | ||
| The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors | Q27860900 | ||
| Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA | Q28118718 | ||
| Cytoplasmic DNA innate immune pathways | Q28246926 | ||
| Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years | Q28255234 | ||
| Coordinated regulation of accessory genetic elements produces cyclic di-nucleotides for V. cholerae virulence | Q28485721 | ||
| The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response | Q28510485 | ||
| Inflammasomes in health and disease | Q29616356 | ||
| Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice | Q30402980 | ||
| Adjuvant solution for pandemic influenza vaccine production | Q30422038 | ||
| Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen | Q33314599 | ||
| cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. | Q34084866 | ||
| HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates | Q34085119 | ||
| The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides | Q34151349 | ||
| 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential | Q34303159 | ||
| STING and the innate immune response to nucleic acids in the cytosol | Q34317532 | ||
| Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid | Q34339243 | ||
| The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING | Q34346633 | ||
| Regulation of adaptive immunity by the innate immune system | Q34659642 | ||
| Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity | Q34796825 | ||
| Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | Q34802680 | ||
| Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. | Q34875973 | ||
| Identification and characterization of a loss-of-function human MPYS variant | Q35022308 | ||
| Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 | Q35090905 | ||
| Cytosolic entry controls CD8+-T-cell potency during bacterial infection | Q35217477 | ||
| Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans | Q35669097 | ||
| The importance of adjuvant formulation in the development of a tuberculosis vaccine | Q35783475 | ||
| Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia | Q36097274 | ||
| Crystallization studies of the murine c-di-GMP sensor protein STING | Q36143536 | ||
| Vaccine Adjuvants: Putting Innate Immunity to Work | Q36168232 | ||
| The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis | Q36229527 | ||
| Using macrophage activation to augment immunotherapy of established tumours | Q36747346 | ||
| c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. | Q37109444 | ||
| New horizons in adjuvants for vaccine development | Q37342049 | ||
| Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system | Q37555597 | ||
| The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant | Q37701568 | ||
| Adjuvants for cancer vaccines | Q37757731 | ||
| Recent advances in the development of novel mucosal adjuvants and antigen delivery systems | Q37791336 | ||
| Assessing the safety of adjuvanted vaccines | Q37906961 | ||
| RIG-I like receptors in antiviral immunity and therapeutic applications | Q37945229 | ||
| Innate immune pathways triggered by Listeria monocytogenes and their role in the induction of cell-mediated immunity | Q37975705 | ||
| Human Monocytes Promote Th1 and Th17 Responses to Streptococcus pneumoniae | Q38629727 | ||
| Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3',5'-cyclic diguanylic acid | Q40971124 | ||
| Evidence for a cyclic diguanylic acid-dependent cellulose synthase in plants | Q41144976 | ||
| Convenient Synthesis of a Propargylated Cyclic (3′-5′) Diguanylic Acid and Its “Click” Conjugation to a Biotinylated Azide | Q41469448 | ||
| One-flask syntheses of c-di-GMP and the [Rp,Rp] and [Rp,Sp] thiophosphate analogues | Q42732138 | ||
| The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant | Q43198955 | ||
| Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant | Q44205583 | ||
| Bacterial c-di-GMP is an immunostimulatory molecule | Q44754791 | ||
| Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer | Q44915586 | ||
| c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. | Q46030297 | ||
| Vaccines for the twenty-first century society | Q51664205 | ||
| The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives | Q68483799 | ||
| The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties | Q79450264 | ||
| Synthesis of 3',5'-cyclic diguanylic acid (cdiGMP) using 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl as a protecting group for 2'-hydroxy functions of ribonucleosides | Q79965922 | ||
| Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP | Q81981030 | ||
| 3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection | Q84250609 | ||
| Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction | Q84276325 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine development | Q27133094 |
| P304 | page(s) | 131-43 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Therapeutic advances in vaccines | Q26842222 |
| P1476 | title | Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants | |
| P478 | volume | 1 |
| Q46094829 | A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. |
| Q47573396 | A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination |
| Q91642540 | Advances in immunotherapy delivery from implantable and injectable biomaterials |
| Q38788154 | Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells |
| Q57291393 | Assessment of Th1/Th2 bias of STING agonists coated on microneedles for possible use in skin allergen immunotherapy |
| Q47359765 | Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy |
| Q38719858 | Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators |
| Q98177707 | Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner |
| Q28551420 | Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses |
| Q55224227 | Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic Toxoplasmosis. |
| Q58599357 | Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer |
| Q40339226 | Cyclic Dinucleotides in the Scope of the Mammalian Immune System |
| Q33773787 | DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization |
| Q43923587 | Dendritic cell therapy in melanoma. |
| Q35634752 | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity |
| Q91142865 | Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy |
| Q89065038 | Exploiting vita-PAMPs in vaccines |
| Q47169865 | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization. |
| Q38711286 | Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model |
| Q33556636 | Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge. |
| Q59351768 | Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy |
| Q40103816 | Listening to each other: Infectious disease and cancer immunology |
| Q35836140 | Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. |
| Q35569805 | OASes and STING: adaptive evolution in concert |
| Q90315050 | Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma |
| Q64071164 | Priming of HIV-1-specific CD8 T cells with strong functional properties from naïve T cells |
| Q35858368 | STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade |
| Q55399721 | STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice. |
| Q92664085 | STING modulators: Predictive significance in drug discovery |
| Q100395390 | STING regulates BCR signaling in normal and malignant B cells |
| Q38293111 | STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy? |
| Q52714689 | STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection |
| Q26776009 | STING: infection, inflammation and cancer |
| Q53047113 | Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. |
| Q46189367 | Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control |
| Q90307219 | Stimulator of interferon genes agonists attenuate type I diabetes progression in NOD mice |
| Q43170567 | Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins. |
| Q36350923 | TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. |
| Q64989143 | TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. |
| Q64229218 | The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization |
| Q92571706 | The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders |
| Q38275607 | The STING controlled cytosolic-DNA activated innate immune pathway and microbial disease |
| Q36857386 | The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons |
| Q50988785 | Therapeutic cancer vaccines |
| Q38570333 | Translating nucleic acid-sensing pathways into therapies |
| Q38553065 | Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure |
| Q61811648 | Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses |
| Q26796314 | Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges |
| Q98289837 | cGAS-STING pathway in oncogenesis and cancer therapeutics |
Search more.